Agomelatine-Mood Stabilizer Combinations for Mood Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mood disorders such as major depressive disorder, cyclothymic disorder, and dysthymic disorder are inadequate as existing molecules fail to fully address these conditions and often come with significant side effects, necessitating the development of new alternative treatments.
Innovation Solution
The association of agomelatine or its hydrates, crystalline forms, and addition salts with a pharmaceutically acceptable acid or base, combined with a mood-regulating agent like lithium, carbamazepine, or valproate, is used to create pharmaceutical compositions for effective treatment of these disorders, leveraging agomelatine's dual action as a melatoninergic agonist and 5-HT 2C receptor antagonist.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing molecules are used to treat mood disorders, then treatment coverage is limited, but side effects are significant
Solution Approach 1:
The patent combines agomelatine with mood stabilizers (lithium, carbamazepine, valproate) or atypical antipsychotics to create a composite therapeutic regimen. This merging of substances with complementary mechanisms of action achieves broader treatment coverage for mood disorders while maintaining a favorable side effect profile, as each component contributes different therapeutic benefits that reinforce each other
2Adaptability or versatility
If existing molecules are used to treat mood disorders, then treatment options are limited, but developing new treatments is necessary
Solution Approach 1:
The patent establishes a universal treatment approach where agomelatine serves as a core component that can be combined with multiple different mood stabilizers and antipsychotics. This multi-functional combination strategy allows the same base substance (agomelatine) to be adapted for treating various mood disorders including bipolar disorder, major depressive disorder, and schizoaffective disorder, providing broad versatility without requiring entirely new treatments for each condition
Data Source
AI summary
Association comprises: agomelatine (N-[2-(7-methoxy-1-naphtyl)ethyl]acetamide) or its hydrate, crystalline, acid or base salts; and thymoregulating agent. ACTIVITY : Hypnotic; Antidepressant; Cardiovascular-Gen; Neuroleptic; Anorectic; Gastrointestinal-Gen; CNS-Gen. MECHANISM OF ACTION : Melatoninergic receptor system agonist; Hydroxytryptamine receptor antagonist.